These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8497207)

  • 1. Oncoscint for detection of disseminated colorectal and ovarian cancer.
    Med Lett Drugs Ther; 1993 Jun; 35(898):52-3. PubMed ID: 8497207
    [No Abstract]   [Full Text] [Related]  

  • 2. OncoScint image atlas.
    Maguire RT
    Targeted Diagn Ther; 1992; 6():141-75. PubMed ID: 1576344
    [No Abstract]   [Full Text] [Related]  

  • 3. OncoScint CR103 imaging in the surgical management of patients with colorectal cancer.
    Doerr RJ; Abdel-Nabi HH
    Targeted Diagn Ther; 1992; 6():89-109. PubMed ID: 1576352
    [No Abstract]   [Full Text] [Related]  

  • 4. [Indium 111-labeled antibodies in the detection of colorectal carcinoma].
    Artiko V; Obradović V; Davidović B; Petrović N; Petrović M; Krivokapić Z; Pavlov M; Adanja G; Sobić D; Vlajković M; Pavlović S; Rebić R
    Acta Chir Iugosl; 2003; 50(4):43-6. PubMed ID: 15307496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioimmunodetection of colorectal carcinoma.
    Artiko V; Obradovic V; Davidovic B; Petrovic N; Petrovic M; Krivokapic Z; Kecmanovic D; Pesko P; Djukic V; Milosavljevic T; Adanja G; Vlajkovic M
    Hepatogastroenterology; 2003; 50(52):1029-31. PubMed ID: 12845972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of 111In-CYT-103 on the surgical management of patients with ovarian cancer.
    Surwit EA
    Targeted Diagn Ther; 1992; 6():125-40. PubMed ID: 1576343
    [No Abstract]   [Full Text] [Related]  

  • 7. Challenges in immunoscintigraphy of ovarian cancer.
    Kim EE; Kasi LP
    Gynecol Oncol; 1993 Mar; 48(3):283-4. PubMed ID: 8462895
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical experience with radiolabelled monoclonal antibodies in the detection of colorectal and ovarian carcinoma recurrence and review of the literature.
    Pinkas L; Robins PD; Forstrom LA; Mahoney DW; Mullan BP
    Nucl Med Commun; 1999 Aug; 20(8):689-96. PubMed ID: 10451876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter clinical trial of 111In-CYT-103 in patients with ovarian cancer.
    Gallup DG
    Targeted Diagn Ther; 1992; 6():111-24. PubMed ID: 1576342
    [No Abstract]   [Full Text] [Related]  

  • 10. Monoclonal antibody imaging in colon cancer: a transition from basic science to clinical application.
    Kim SL; Goldschmid S
    Am J Gastroenterol; 1994 Oct; 89(10):1910-2. PubMed ID: 7942701
    [No Abstract]   [Full Text] [Related]  

  • 11. Indium-111 OncoScint CR/OV and F-18 FDG in colorectal and ovarian carcinoma recurrences. Early observations.
    Bohdiewicz PJ; Scott GC; Juni JE; Fink-Bennett D; Wilner F; Nagle C; Dworkin HJ
    Clin Nucl Med; 1995 Mar; 20(3):230-6. PubMed ID: 7750217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of recurrent colorectal carcinoma with In-111 CYT-103 scintigraphy in a patient with nondiagnostic MRI and CT.
    Edlin JP; Kahn D
    Clin Nucl Med; 1994 Nov; 19(11):1004-7. PubMed ID: 7842571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative analysis of In-111 satumomab pendetide immunoscintigraphy. An aid to visual interpretation of images in patients with suspected carcinomatosis.
    Neal CE; Johnson DL; Cornwell VL; Markwell S
    Clin Nucl Med; 1996 Aug; 21(8):638-42. PubMed ID: 8853918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 111In-CYT-103 immunoscintigraphy in ovarian cancer.
    Cannistra SA
    Gynecol Oncol; 1993 Nov; 51(2):292-4. PubMed ID: 8276314
    [No Abstract]   [Full Text] [Related]  

  • 15. Site of mistletoe injection observed on In-111 OncoScint imaging.
    Choe W
    Clin Nucl Med; 1997 Feb; 22(2):127. PubMed ID: 9031776
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical assessment of 111In-CYT-103 immunoscintigraphy in ovarian cancer.
    Surwit EA; Childers JM; Krag DN; Katterhagen JG; Gallion HH; Waggoner S; Mann WJ
    Gynecol Oncol; 1993 Mar; 48(3):285-92. PubMed ID: 8462896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of iodine-123-vasoactive intestinal peptide receptor scintigraphy and indium-111-CYT-103 immunoscintigraphy.
    Raderer M; Becherer A; Kurtaran A; Angelberger P; Li S; Leimer M; Weinlaender G; Kornek G; Kletter K; Scheithauer W; Virgolini I
    J Nucl Med; 1996 Sep; 37(9):1480-7. PubMed ID: 8790198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter clinical trials of monoclonal antibody B72.3-GYK-DTPA 111In (111In-CYT-103; OncoScint CR103) in patients with colorectal carcinoma.
    Abdel-Nabi HH; Doerr RJ
    Targeted Diagn Ther; 1992; 6():73-88. PubMed ID: 1576351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of the radiolabeled murine monoclonal antibody, 111In-CYT-103, in the management of colon cancer.
    Petersen BM; Bass BL; Bates HR; Chandeysson PL; Harmon JW
    Am J Surg; 1993 Jan; 165(1):137-42; discussion 142-3. PubMed ID: 8418688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT.
    Collier BD; Abdel-Nabi H; Doerr RJ; Harwood SJ; Olsen J; Kaplan EH; Winzelberg GG; Grossman SJ; Krag DN; Mitchell EP
    Radiology; 1992 Oct; 185(1):179-86. PubMed ID: 1523304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.